In this study, we provide evidence that PTPRO as a potential immune indicator and PTPRO-related CD8+ T-cell signatures (PTSs) can be used to predict prognosis and immunotherapy response in breast cancer patients. This evidence concerns the gene PTPRO and breast cancer.